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ABSTRACT
Allogeneic progenitor cell transplantation is the only curative therapy for patients with refractory acute
myelogenous leukemia or myelodysplastic syndromes. To identify prognostic factors in these patients, we
performed a retrospective analysis of transplantation outcomes. Patients were selected if they had undergone
an allogeneic transplantation between January 1988 and January 2002 and were not in remission or first
untreated relapse at the time of transplantation. A total of 135 patients were identified. The median age was
49.5 years (range, 19-75 years). At the time of transplantation, 39.3% of patients had not responded to
induction therapy, 37% had not responded to first salvage therapy, and 23.7% were beyond first salvage.
Forty-one patients (30%) received unrelated donor progenitor cells. Eighty patients (59%) received either a
reduced-intensity or a nonmyeloablative regimen. A total of 104 (77%) of 135 patients died, with a median
survival time of 4.9 months (95% confidence interval, 3.9-6.6 months). The median progression-free survival
was 2.9 months (95% confidence interval, 2.5-4.2 months). A Cox regression analysis showed that Karnofsky
performance status, peripheral blood blasts, and tacrolimus exposure during the first 11 days after transplan-
tation were predictive of survival. These data support the use of allogeneic transplantation for patients with
relapsed or refractory acute myelogenous leukemia/myelodysplastic syndromes and suggest that optimal
immune suppression early after transplantation is essential for long-term survival even in patients with
refractory myeloid leukemias.
© 2005 American Society for Blood and Marrow Transplantation
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pNTRODUCTION
Advances in chemotherapy have improved out-
omes for patients with acute myeloid leukemia
AML) or myelodysplastic syndromes (MDS) [1,2].
espite increases in complete remission rates, how-
ver, most patients with diploid or poor-risk cytoge-
etics will relapse after primary therapy [1,2]. Al- m
08hough response rates with salvage therapy in patients
ith AML/MDS after failure of primary chemother-
py have been discouraging, allogeneic transplanta-
ion has generally been associated with high complete
emission rates and the potential to achieve long-term
isease control [3-8]. However, relapse after trans-
lantation remains the most important cause of treat-
ent failure in this setting and is generally associated
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Prognostic Factors for Refractory or Relapsed AML or MDS
Bith poor survival [5-11]. The incidence of disease
ecurrence after allogeneic transplantation has not
hanged with time [5,6]. Modiﬁcations of the prepar-
tive regimen by using various combinations of che-
otherapy and radiotherapy have failed to reduce the
isk of relapse without an increase in nonrelapse mor-
ality [12].
The most important predictor of leukemia relapse
fter allogeneic transplantation is disease status at the
ime of transplantation. Relapse rates are 2 to 3 times
igher in patients not in remission at the time of trans-
lantation as compared with rates in those in remission
13,14]. Among patients not in remission, patients with
rimary induction failure tend to have better outcomes
han those whose disease has relapsed and failed to re-
pond to reinduction therapy [7,8,14-16].
Notwithstanding, long-term disease control is
ossible after allogeneic transplantation for refractory
r relapsed AML/MDS. It is likely that the risk of
elapse differs according to disease- and patient-spe-
iﬁc characteristics. It is also possible that the degree
f immune suppression, as deﬁned by the serum levels
f either cyclosporine or tacrolimus, may also affect
ransplantation outcomes in this patient population,
ecause patients with lower levels may experience a
ore potent graft-versus-leukemia effect, and ran-
omized trials have shown lower relapse rates in pa-
ients who receive lower doses of cyclosporine
13,17,18]. To identify prognostic factors in patients
ith relapsed or refractory leukemia and to deﬁne the
redictive role of the levels of immune suppression as
etermined by tacrolimus blood levels, we performed
retrospective analysis of transplantation outcomes of
atients with AML/MDS undergoing allogeneic
ransplantation who were not in remission at the time
f transplantation and were beyond ﬁrst salvage ther-
py. Herein are the results of this analysis.
ATIENTS AND METHODS
The Department of Blood and Marrow Trans-
lantation at M.D. Anderson Cancer Center main-
ains a prospective database of all patients who have
ndergone a progenitor cell transplantation in the
nstitution. The database incorporates a variety of
ore pretransplantation and posttransplantation vari-
bles used for both prospective and retrospective anal-
sis. Patients were selected for this analysis if they
ulﬁlled all of the following criteria: (1) were diag-
osed with AML or MDS; (2) underwent an alloge-
eic transplantation from a sibling-matched, a 1 anti-
en–related mismatched, or a matched unrelated
onor at any time between January 1988 and January
002 with 1 of the following conditioning regimens:
udarabine/melphalan, ﬂudarabine/idarubicin/cytara-
ine, thiotepa/busulfan/cyclophosphamide, busulfan/ t
B&MTyclophosphamide, or cyclophosphamide/etoposide/
otal body irradiation; and (3) were not in remission or
rst untreated relapse at the time of transplantation.
emission was deﬁned as morphologically normal
one marrow, without cytogenetic evidence of leuke-
ia, and a morphologically normal peripheral blood
mear with recovery of peripheral blood hematologic
alues, including a platelet count 100  109/L and
n absolute neutrophil count 1.5  109/L.
All patients were treated on institutional review
oard–approved protocols that were active at the time.
atients and donors signed written informed consent,
nd unrelated donor cells were consented and pro-
ured under the auspices of the National Marrow
onor Program by following guidelines that were
pplicable at the time. Approval to perform this ret-
ospective analysis was obtained from the institutional
eview board according to current institutional guide-
ines.
Tacrolimus and cyclosporine levels were moni-
ored 2 to 3 times weekly. Trough tacrolimus levels
ere measured by using an immunoassay (Abbott
harmaceutical, Irving, TX). The tacrolimus dose was
djusted to maintain trough levels between 5 and
0 ng/dL. In patients receiving cyclosporine, doses
ere adjusted to maintain levels of 150 to 300 ng/dL
s measured by radioimmuoassay for the parent drug.
upportive care and antibacterial, antifungal, and an-
iviral prophylaxis followed the institutional protocols
nd guidelines that were active at the time.
Unadjusted survival probabilities were estimated
y using the method of Kaplan and Meier [19]. Un-
djusted between-group survival time comparisons
ere made by using the log-rank test [20]. Univariate
nalyses were performed for a variety of pretransplan-
ation and transplantation variables related to overall
urvival, event-free survival (EFS), and nonrelapse
ortality. The Cox proportional hazards (PH) regres-
ion model was used to assess the ability of patient
haracteristics or treatment-related variables to pre-
ict survival [21]. Regression analysis of the survival
imes was begun by examining a martingale residual
lot for each numeric-valued candidate predictor vari-
ble, smoothed by using the lowess method of Cleve-
and [22], and predictive variables were transformed as
uggested by these plots. Multivariate Cox models
ere obtained by ﬁrst performing a forward selection
ith a P-value cutoff of .05. The most predictive
dditional variable was allowed to enter the model if
ts partial P value was .05. Association between dis-
rete variables was assessed by the Fisher exact and
eneralized exact tests. All computations were per-
ormed in Splus by using standard Splus functions [23]
nd the Splus survival analysis package of Therneau [24].
Tacrolimus exposure during the ﬁrst 100 days
fter transplantation was determined by plotting all
acrolimus levels against time to transplantation. The
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1rea under the curve (AUC) of tacrolimus levels over
ime was derived by using standard methods. For each
f several initial time periods, varying from 1 to 50
ays, the AUC formed by tacrolimus levels over a
able 1. Patient and Treatment Characteristics (N  135)
Variable n (%)
Median
(Range)
ex
Female 58 (43.0)
Male 77 (57.0)
ge at BMT (y) 49.5 (19-75)
iagnosis
AML 93 (68.9)
MDS 24 (17.8)
MDS/AML 18 (13.3)
o. prior therapies 2 (0-9)
isease status before SCT
Primary induction failure 53 (39.3)
First relapse refractory 50 (37.0)
>First relapse refractory 32 (23.7)
ytogenetics
Good 4 (3.0)
Intermediate 63 (46.7)
Bad 62 (45.9)
Missing 6 (4.4)
ubrod performance status before
transplantation
0 22 (16.3)
1 98 (72.6)
2 13 (9.6)
Missing 2 (1.5)
tem cell type
BM 69 (51.1)
PBPC 66 (48.9)
onor type
Related 94 (69.6)
Matched unrelated 41 (30.4)
onor sex
Female 64 (47.4)
Male 71 (52.6)
onditioning regimen
Fludarabine/melphalan 43 (31.9)
Fludarabine/idarubicin/cytarabine 16 (11.9)
Fludarabine/busulfan 21 (15.6)
Cyclophosphamide/TBI  others 7 (5.2)
Busulfan/cyclophosphamide 
others 48 (35.6)
onablative or reduced-intensity
conditioning
Yes 80 (59)
No 55 (41)
VHD prophylaxis
Tacrolimus based 107 (79.3)
Cyclosporine based 28 (20.7)
BM blasts before SCT 23 (0-100)
PB blasts before SCT 6 (0-99)
bsolute PB blast count before
SCT 114 (0-60 670)
lbumin before SCT, g/dL 3.4 (2.3-4.7)
CT indicates stem cell transplantation; AML, acute myelogenous
leukemia; MDS, myelodysplastic syndrome; TBI, total body
irradiation; GVHD, graft-versus-host disease; BM, bone mar-
row; PB, peripheral blood; BMT, bone marrow transplantation;
PBPC, peripheral blood progenitor cells.peciﬁc time period was used as a surrogate for ta-
10rolimus exposure, and this value was then analyzed as
potential predictor of transplantation outcomes. For
he analyses summarized here, a quadratic function of
 log(AUC of tacrolimus levels for the ﬁrst 11 days after
ransplantation) was used—speciﬁcally, b1Z  b2Z
2,
ecause this provided the best prediction of survival
ime among all values considered.
ESULTS
atient and Treatment Characteristics
A total of 135 patients were identiﬁed who fulﬁlled
ur eligibility criteria. Patient and treatment charac-
eristics are summarized in Table 1. In brief, the
edian age of the patients at the time of transplanta-
ion was 49.5 years (range, 19-75 years), the median
ime to transplantation was 12 months (range, 0.9-54
onths), and the median number of prior therapies
efore transplantation for refractory disease was 2
range, 0-9). At the time of transplantation, 39.3% of
atients had not responded to induction therapy, 37%
ad not responded to ﬁrst salvage therapy, and 23.7%
ere beyond ﬁrst salvage. Forty-six percent of patients
ad poor-risk cytogenetic abnormalities, as deﬁned by
artial or complete deletion of chromosomes 5 or 7,
risomy 8, abnormalities of chromosome 11, presence
f t(9,22), or complex (3) cytogenetic abnormalities.
Forty-one patients (30%) received unrelated do-
or progenitor cells. Eighty patients (59%) received
ither a reduced-intensity or a nonmyeloablative reg-
men, whereas the remaining 55 patients (41%) re-
eived a myeloablative regimen that included either
usulfan/cyclophosphamide combinations or total body
rradiation. The nonmyeloablative or reduced-intensity
onditioning regimens were ﬂudarabine/melphalan, ﬂu-
arabine/idarubicin/cytarabine, or ﬂudarabine/busul-
an combinations. Graft-versus-host disease (GVHD)
rophylaxis consisted primarily of tacrolimus/metho-
rexate (79.3% of patients) and cyclosporine combina-
ions (in the remaining 20.7%).
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Prognostic Factors for Refractory or Relapsed AML or MDS
Burvival
A total of 104 (77%) of 135 patients died, with
edian survival time of 4.9 months (95% conﬁdence
nterval, 3.9-6.6 months; Figure 1). Univariate survival
nalyses within patient subgroups are summarized in
able 2. The most important individual predictors of
short survival were 2 prior therapies, Zubrod per-
ormance status of 2, high peripheral blood blast
ount, low peripheral blood platelets, and low albu-
able 2. Univariate Analysis of Transplantation Outcomes
Variable (% at
ge at BMT (y)
<50
>50
iagnosis
AML
MDS
MDS/AML
o. prior therapies
<2
>2
isease status before SCT
Primary induction failure
First relapse refractory
>First relapse refractory
ytogenetics
Good
Intermediate
Bad
ubrod performance status before SCT P
0–1
2 N
tem cell type
BM
PBPC
onor type
Related
Matched unrelated
Mismatched related
onablative or reduced-intensity conditioning
Yes
No
BM blasts before SCT
<10% (n  58)
>10% (n  60)
bsolute PB blast count before SCT
<100/L (n  73)
>100/L
B platelets before SCT
<30 (n  65)
>30 (n  70)
lbumin before SCT, g/dL P
<3.4 (n  60)
>3.4 (n  75)
UC tacrolimus day 11
>94.8
<94.8
RM indicates nonrelapse mortality; BMT, bone marrow trans
syndrome; SCT, stem cell transplantation; NA, not applicable; B
blood; AUC, area under the curve.in. h
B&MTisease-Free Survival
A total of 111 (82%) patients either died or had
isease progression. The median progression-free
urvival was 2.9 months (95% conﬁdence interval,
.5-4.2 months; Figure 2). On univariate analysis
Table 2), the most important predictors for a short
rogression-free survival were2 prior therapies, dis-
ase status beyond refractory ﬁrst relapse, Karnofsky
erformance status 1, 10% bone marrow blasts,
0 d)
Survival
(% at 1/2 y)
Event-Free Survival
(% at 1/2 y)
32/25 22/16
26/22 23/21
28/24 22/18
29/21 17/17
32/26 32/27
P  .03 P  .02
40/34 30/30
24/19 19/14
P  .05
36/29 26/26
26/19 22/17
20/20 16/8
P  .10
25/NA 25/NA
32/30 25/23
25/18 18/15
1 P  .0002 P  .001
32/26 25/21
0/NA NA/NA
31/26 25/21
26/20 19/15
31/25 23/20
28/24 24/19
17/NA 8/NA
27/22 24/20
31/25 20/16
P  .02
37/29 30/28
25/21 18/14
P  .01 P  .001
36/32 30/28
22/15 15/10
P  .01
22/16 16/14
35/30 27/22
1 P  .0003 P  .001
18/15 15/11
37/30 28/25
34/27 23/19
27/23 23/21
ion; AML, acute myelogenous leukemia; MDS, myelodysplastic
e marrow; PBPC, peripheral blood progenitor cells; PB, peripheralNRM
180/36
59/52
54/54
60/57
46/46
63/50
55/55
60/53
62/62
55/45
53/53
38/NA
66/62
49/49
 .00
60/56
A/NA
59/55
56/51
65/62
43/38
63/NA
53/49
63/59
60/54
56/52
58/55
56/51
P  10
50/45
63/59
 .00
43/39
68/65
62/62
51/46
plantat
M, bonigh peripheral blood blast count, and low albumin.
111
Nm
i
t
d
E
T
ﬁ
3
a
3
3
v
M
s
r
t
t
m
s
o
r
r
a
d
r
i
o
t
t
e
w
K
b
a
h
l
w
o
a
o
t
d
s
b
d
s
s
p
t
t
F
v
T
1
P
l
l
l
P
T
(
P
F
l
l
l
P
R. Wong et al.
1onrelapse Mortality
Nonrelapse mortality for all patients was 30% at 6
onths and 43% at 12 months (Figure 3). On univar-
ate analysis, a low albumin level before transplanta-
ion and a Karnofsky performance status of 1 pre-
icted higher nonrelapse mortality.
ffect of Immune-Suppressive Levels after
ransplantation
The median AUC of tacrolimus levels during the
rst 11 days after transplantation was 94.8 (range,
6.9-210.2). On univariate analysis, tacrolimus levels
bove or below the median were associated with a
8% versus 54% 1-year nonrelapse mortality rate, a
4% versus 27% 1-year survival rate, and a 23%
ersus 23% EFS rate, respectively.
ultivariate Analysis
Fitted multivariate Cox PH models for overall
urvival and EFS are summarized in Tables 3 and 4,
espectively. The Cox PH regression analysis showed
hat performance status, peripheral blood blasts, and
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Figure 2. Kaplan-Meier curve for event-free survival.
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igure 3. Kaplan-Meier curve for nonrelapse mortality–free sur-
ival.
12acrolimus exposure as deﬁned by the AUC of tacroli-
us levels during the ﬁrst 11 days were predictive of
urvival. As noted previously, tacrolimus exposure
ver the ﬁrst 11 days (AUC) had a log quadratic
elationship with the log hazard of death; the death
ate initially decreased with AUC but then increased
t higher levels. It is important to note that the pre-
icted survival probabilities with any cutoff time in the
ange of 11 to 15 days were very near the correspond-
ng predicted probabilities for the optimal 11-day cut-
ff. Thus, in terms of the ability to predict survival
ime, the total amount of tacrolimus over any initial
ime period in this range should predict outcome
qually well. A similar pattern was seen with EFS in
hich, in addition to 11-day tacrolimus exposure, a
arnofsky performance status of 1, disease status
eyond ﬁrst relapse, and peripheral blood blasts were
lso predictive. These statistical results should not,
owever, be construed to imply that GVHD prophy-
axis may be discontinued after 15 days, because that
as not done with these patients, but rather that
ptimal immune suppression during the ﬁrst 15 days
fter transplantation favorably affects transplantation
utcomes. Our data would suggest that to maintain
he optimal tacrolimus exposure during the ﬁrst 15
ays after transplantation, the optimal target range of
erum tacrolimus levels during these days should be
etween 7 and 9 ng/dL.
Figure 4 illustrates the manner in which the pre-
icted EFS probability under the ﬁtted Cox PHmodel
ummarized in Table 4 varies with tacrolimus expo-
ure and peripheral blood blasts. Within each row, the
lots correspond to the 10th, 50th, and 90th percen-
ile of the tacrolimus exposure. These plots show that
acrolimus exposures that are either too low or too
able 3. Cox Proportional Hazards Model for Overall Survival (N 
35; 104 Deaths)
Variable Coefficient SE P Value
S  2 1.13 0.35 .001
og (PB blasts) 0.15 0.06 .02
og (AUC up to day 11) 0.27 0.36 .002
og (AUC up to day 11)^2 3.10 0.79
S indicates performance status; PB, peripheral blood; AUC, area
under the curve.
able 4. Cox Proportional Hazards Model for Event-Free Survival
N  135; 111 Events)
Variable Coefficient SE P Value
S  2 1.22 0.35 .0004
irst relapse refractory 0.67 0.26 .01
og (PB blasts) 0.18 0.06 .005
og (AUC up to day 11) 0.14 0.35 .001
og (AUC up to day 11)^2 2.65 0.78
S indicates performance status; PB, peripheral blood; AUC, area
under the curve.
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Prognostic Factors for Refractory or Relapsed AML or MDS
Bigh may adversely affect transplantation outcomes
egardless of tumor burden, as deﬁned by peripheral
lood blasts, although the magnitude of the effect may
e more important for patients with a low tumor
urden. Our data suggest that the optimal range of
erum tacrolimus levels during the ﬁrst 15 days would
e between 7 and 9 ng/dL, regardless of other prog-
ostic factors, in patients with refractory or relapsed
yeloid leukemias.
ISCUSSION
Allogeneic transplantation is the only curative op-
ion for patients with refractory AML/MDS. Not-
ithstanding, long-term disease control is achieved in
nly a small fraction of patients with refractory leu-
emia who undergo this procedure [7,8,15,16]. This
etrospective analysis conﬁrms results published in
ther single-institution studies and registry analyses.
articularly, patients with primary induction failure
end to have better outcomes than patients with re-
ractory relapsed disease.
This analysis is the ﬁrst to include a large propor-
ion of patients with refractory AML/MDS who re-
eived allografts after a reduced-intensity or nonabla-
ive regimen. These data suggest that for patients with
efractory AML/MDS, the use of a reduced-intensity
egimen is associated with outcomes similar to those
f patients receiving a more intense ablative regimen.
owever, because this was a retrospective analysis, the
esults should be viewed with caution and should stim-
late the development and implementation of further
                     AUC Tacro 10
th
 percentile AUC Tacro 50
th
percentile AUC Tacro 90
th
percentile
igure 4. Effect of tacrolimus AUC on event-free survival. Row 1
ncludes patients with a peripheral blood blast count of 0 and is
odeled with a tacrolimus AUC at the 10th, 50th, and 90th per-
entiles. Row 2 depicts outcomes for patients with an absolute
eripheral blood blast count of 80/dL.rospective trials. f
B&MTThe primary cause of treatment failure after allo-
eneic transplantation for patients with refractory
ML/MDS is recurrent disease. Our data, as well as
xperiences from other centers, demonstrate that
50% of relapses occur within the ﬁrst 3 months after
tem cell transplantation. Thus, strategies that are
imed at improving transplantation outcomes in this
atient population must be implemented very early
fter transplantation and must target disease recurrence.
ur analyses indicate that a strategy of reducing immune
uppression to enhance a graft-versus-leukemia effect
arly after transplantation, unfortunately, will be as-
ociated with inferior treatment outcomes and that, at
east during the ﬁrst 10 to 15 days, tacrolimus levels
hould be maintained within therapeutic ranges to
educe early nonrelapse mortality. Whether rapid im-
une suppression withdrawal after that time could
mprove outcomes was not addressed in this study and
equires further exploration.
Immune manipulation through dose reduction of
mmunosuppression has been studied previously. Sul-
ivan et al. [25,26] reported on 16 patients with refrac-
ory or relapsed leukemia who underwent an allograft
ithout any posttransplantation GVHD prophylaxis.
he incidence of acute GVHD was 100%, and the
urvival rate was 37% at 18 months. Our results con-
erning the importance of immune suppressive levels
uring the ﬁrst 10 days after transplantation conﬁrm
hose reported by Bacigalupo et al. [27], who per-
ormed a randomized trial of high-dose versus low-
ose cyclosporine in patients with myeloid leukemias
ho were undergoing allografting. The EFS rate was
uperior in patients randomized to receive the lower
yclosporine dose of 1 mg/kg (49% versus 27%), be-
ause of a lower relapse rate in the low-dose arm. It is
nteresting to note that in that study, there were no
igniﬁcant differences in cyclosporine serum levels
fter the ﬁrst month after transplantation.
We hypothesized that the leukemic burden, as
easured by the peripheral blood blast count, and
one marrow leukemia inﬁltrate would be important
rognostic factors for outcome. Univariate analysis
uggested that these factors could play a role in overall
urvival and EFS, but only peripheral blood blast
ount was predictive on multivariate analysis. This
uggests that leukemic burden may contribute to
ransplantation outcomes and that developing strate-
ies that could safely achieve leukemia burden reduc-
ion, without undue delay of the initiation of the
reparative regimen, may be worthwhile to explore.
t M.D. Anderson Cancer Center, we are exploring
emtuzumab administration 12 days before initiation
f a reduced-intensity regimen of ﬂudarabine/melpha-
an to further pursue this hypothesis.
In summary, these data support the use of alloge-
eic transplantation for patients with relapsed or re-
ractory AML/MDS; however, patients with a very
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1oor performance status should be encouraged to seek
ontransplantation therapies or palliative care because
he likelihood of beneﬁting from allografting is small.
ll patients should be treated under the umbrella of a
linical trial aimed at exploring or deﬁning the role of
ew therapeutic strategies.
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